Personalized outreach across five vaccine types cut unsubscribe rates 62%, with nearly half of vaccinated patients acting after just two nudges

KNOXVILLE, Tenn.: Lirio, the first-ever behavioral science and AI-powered behavioral intelligence platform that empowers people to live their healthiest lives, today announced new results from a large-scale vaccination program reaching millions of patients across a leading U.S. retail pharmacy network. The program found that 40% of patients reached through Lirio’s Precision Nudging® technology got vaccinated - representing a more than 20% increase compared with standard pharmacy messaging.

These results come as shifting vaccine guidance, changing public sentiment, and declining uptake have made it increasingly difficult for healthcare organizations to engage patients around preventive care. To keep pace with these changes, Lirio conducted extensive consumer research to understand evolving attitudes toward vaccination and used those insights to inform its outreach strategy for the pharmacy across five vaccine types - flu, COVID-19, RSV, pneumococcal, and shingles - each with different eligibility considerations and patient attitudes.

Rather than relying on broad, one-size-fits-all reminders, Lirio’s research found that personalized messaging reinforcing patients’ right to make their own health decisions resonated regardless of their views on vaccination. Lirio’s AI then used individual signals to assess each patient’s likelihood of taking action or opting out, helping determine whether and when to send a message.

Nearly half of those who ultimately got vaccinated did so after just two nudges, while unsubscribe rates declined 62%, showing how more targeted communication can drive meaningful engagement without sacrificing the patient experience.

“Healthcare organizations are navigating a moment where what worked to engage patients even a year ago may not work today,” said Amy Bucher, Ph.D., Chief Behavioral Officer at Lirio. “The answer isn’t to send more reminders. It’s to better understand what matters to each person and use that insight to determine what to say, when to say it and, importantly, when not to say anything at all. These results show that when you combine behavioral science with AI, you can help more people take action while respecting the choices they make about their health.”

Building on these results, Lirio is continuing to expand its behavioral intelligence platform across payers, health systems, life sciences companies, and retail pharmacies, applying the same approach to challenges ranging from mammography screening to prescription refills and other critical health behaviors.

For more information on Lirio’s Precision Nudging® technology to support patient engagement, please visit lirio.com

About Lirio

Lirio is the first objective-driven, AI-powered behavioral intelligence platform for health and life sciences that orchestrates patient workflows, hyper-personalizes consumer engagement, and measurably improves outcomes. Through evidence-based Precision Nudging® Interventions, Lirio applies behavioral science to each individual's clinical, social, and behavioral context, helping people take the next step in their health journey. Recognized with the 2025 Inc. Best in Business award, including honors for Best in Innovation, Lirio has received multiple awards for its excellence in applied artificial intelligence and is HITRUST® CSF certified, SOC 2 Type II compliant, and NIST certified. For more information, visit www.lirio.com.

Fonte: Business Wire